ST Pharm Co., Ltd.

Form 483 issued November 8, 2018 · Siheung-si, South Korea

Investigator
Michael A. Charles
Observations
3
Pages
2
FEI number
3004161413

In short: On November 8, 2018, FDA issued a Form 483 with 3 observations to ST Pharm Co., Ltd. in Siheung-si, Gyeonggi-do (FEI 3004161413). The investigator was Michael A. Charles. Most observations concern production and quality system; the most-cited regulation is 21 CFR 211.100 (written procedures; deviations).

At a glance

Production and quality system account for 2 of 3 observations.

Production1
Quality system1
Laboratory controls1

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Process validation does not always include inclusion and establishment of all process parameters that should be…

  2. 02

    Written records of investigations into unexplained discrepancies…

  3. 03

    Laboratory controls do not include the establishment of scientifically sound and appropriate procedures designed to assure…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at ST Pharm Co., Ltd.?

FDA listed 3 observations on this Form 483, mostly about production, quality system and laboratory controls. The most-cited regulation is 21 CFR 211.100 (written procedures; deviations). The opening words of each observation are shown on this page.

Who inspected ST Pharm Co., Ltd.?

Michael A. Charles is named on this Form 483. Each investigator has a profile showing what they cite most.

When was ST Pharm Co., Ltd. inspected by FDA?

This Form 483 is dated November 8, 2018.

How do I get the full Form 483 for ST Pharm Co., Ltd.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free